Associations for NA-NSAIDs differ by cancer site and subtype, e.g., with differing results for breast cancer by hormone receptor status (reviewed in [28]), no association observed in a meta-analysis on endometrial cancer [29], and a positive association observed for kidney cancer (reviewed in [30]). Here, NR4A1 is linked to endometrial cancer.